In December 2005, Eli Lilly & Co. pled guilty to a criminal indictment from the Bush Justice Department and paid $36 million in fines and "disgorgement" of its ill-gotten gains. The company's crime was mounting a concerted effort to inform doctors that, according to leading medical authorities, the firm's estrogen-modulating drug Evista substantially reduced the risk of invasive breast cancer in postmenopausal women.
Scott Gottlieb, M.D., is a resident fellow at AEI.
The full text of this article will be available on AEI.org on December 24, 2007. To read the full text of this article, click here (subscription required).